<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404376</url>
  </required_header>
  <id_info>
    <org_study_id>COMBAT-MI</org_study_id>
    <nct_id>NCT02404376</nct_id>
  </id_info>
  <brief_title>COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial</brief_title>
  <acronym>COMBAT-MI</acronym>
  <official_title>COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remote ischemic conditioning (RIC) and intravenous exenatide administered immediately before
      primary angioplasty have been found to limit infarct size in patients with STEMI (ST segment
      elevation myocardial infarction), but the reduction is limited. This study investigates
      whether a combination therapy including both therapies is more effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COMBAT-MI is an investigator-driven, randomized, double-blind and placebo-controlled clinical
      trial aimed at evaluating the effect of Remote Ischemic Conditioning and exenatide, alone and
      in combination, on Myocardial Infarct size in 400 STEMI patients (ST segment elevation
      myocardial infarction). Patients with TIMI (Thrombolysis in Myocardial Infarction) flow grade
      &gt; 1 will be excluded. The study has a 2 x 2 factorial design (Remote Ischemic Conditioning ,
      Exenatide, both or neither). The primary end-point will be Myocardial Infarct size measured
      by Cardiac Magnetic Resonance Imaging (CMRI) performed 3 - 7 days after primary Percutaneous
      Coronary Intervention (pPCI) (expressed as % of left ventricular (LV) mass). Secondary
      end-points will include myocardial salvage index, based on angiographic and CMRI derived
      estimations of the area at risk, and frequency of Major Adverse Cardiovascular Events (MACE)
      and of major adverse events during admission.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Infarct Size</measure>
    <time_frame>3-7 days after pPCI</time_frame>
    <description>MI, measured by late gadolinium enhancement in CMRI 3-7 days after pPCI, and expressed as percent of left ventricular mass.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage index</measure>
    <time_frame>3-7 days after pPCI</time_frame>
    <description>Myocardial salvage index defined as the difference between infarct size and area at risk, defined by the T2 CMRI and expressed as a percent of total LV (Left Ventricular) mass, divided by the area at risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmurality index</measure>
    <time_frame>3-7 days after pPCI</time_frame>
    <description>Transmurality index, defined as the ratio of the mass of myocardium showing late gadolinium enhancement to the mass of the myocardial segment containing it.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular volumes</measure>
    <time_frame>3-7 days after pPCI</time_frame>
    <description>LV (Left Ventricular) end-diastolic volume and LVEF (Left Ventricular Ejection Fraction), as determined by CMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction</measure>
    <time_frame>3-7 days after pPCI</time_frame>
    <description>Volume of myocardium with microvascular obstruction determined by late gadolinium enhancement expressed as percent of infarct size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of successful reperfusion</measure>
    <time_frame>First 90 min after reperfusion</time_frame>
    <description>Markers of successful myocardial reperfusion: ST segment resolution 90 minutes post-pPCI , TIMI flow and frame-count post-pPCI , and TIMI blush grade .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>Hospital discharge and expected average of 1 week, one year follow-up</time_frame>
    <description>MACE rate during hospitalization, defined as death, non-fatal myocardial rupture, or appearance or worsening of heart failure during the hospitalization period and after 1 year of follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Substudy: Biomarker analysis in Hospital Universitari Vall d'Hebron Biobank (HUVH Biobank)</measure>
    <time_frame>pre- pPCI</time_frame>
    <description>To find biomarkers of increased myocardial susceptibility to reperfusion injury in blood samples obtained before PCI</description>
  </other_outcome>
  <other_outcome>
    <measure>PRESPECIFIED SUBGROUP ANALYSIS ACCORDING TO TOTAL ISCHEMIC TIME</measure>
    <time_frame>3-7 days after pPCI</time_frame>
    <description>The effects of treatments will be analysed in the subgroup of patients with a total ischemic time of less than 3 hours and of 3 hours of longer.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>ST Elevation Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Remote Ischemic Conditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote Ischemic Conditioning + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote Ischemic Conditioning + exenatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham Remote Ischemic Conditioning + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sham Remote Ischemic Conditioning + exenatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Intravenous administration of Exenatide</description>
    <arm_group_label>Combined treatment</arm_group_label>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Remote Ischemic Conditioning (RIC)</intervention_name>
    <description>Remote ischemic conditioning with a cuff in the arm</description>
    <arm_group_label>Remote Ischemic Conditioning</arm_group_label>
    <arm_group_label>Combined treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intrevenous administration of Placebo</description>
    <arm_group_label>Remote Ischemic Conditioning</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥18 years of age

          -  STEMI characterized by 2 mm ST segment elevation in 2 or more V1 through V4 leads or
             presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or
             1 mV(millivolt) ST segment elevation in the limb leads (II, III and aVF leads, I, aVL
             leads) and V4-V6.

          -  Patients presenting within 6 hours of chest pain.

        Exclusion Criteria:

          -  Known hypersensitivity to exenatide or any of the excipients

          -  Known contraindication to CMR imaging such as significant claustrophobia, severe
             allergy to gadolinium chelate contrast, severe renal insufficiency (defined as
             estimated glomerular filtration rate [eGFR] (epidermal growth factor receptor) &lt;30
             mL/min/1.73 m2), presence of CMRI contraindicated implanted devices (e.g., pacemaker,
             implanted cardiac defibrillator, cardiac resynchronization therapy device, cochlear
             implant), embedded metal objects (e.g., shrapnel), or any other contraindication for
             CMRI.

          -  Assumed life expectancy &lt; 1 year e.g. due to non-cardiac disease.

          -  TIMI flow grade &gt; 1 at the time of diagnostic coronary angiography. These patients
             will be excluded from the analysis of infarct size but will be included in the safety
             analysis.

          -  Pregnant women

          -  Patients with loss of consciousness or confused, not able to read the information and
             to sign the writting consent

          -  Patients with oro-tracheal intubation

          -  Patients with cardiogenic shock persisting 48h after reperfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David García-Dorado, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David García-Dorado, MD, PhD, Professor</last_name>
    <phone>+34932746070</phone>
    <email>dgdorado@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David García- Dorado, MD, PhD, Professor</last_name>
    <phone>+34932746070</phone>
    <email>dgdorado@vhebron.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Bayés Genís, MD, PhD</last_name>
      <phone>+34 93 497 89 15</phone>
      <email>abayesgenis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antoni Bayés- Genís, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduard Fernández-Nofrerias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón González Juanatey, MD, PhD</last_name>
      <email>Jose.Ramon.Gonzalez.Juanatey@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan García Picart, MD</last_name>
      <email>JGarciaPi@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Valle de Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerad Marti, MD</last_name>
      <phone>+34 93 274 6134</phone>
      <phone_ext>6134</phone_ext>
      <email>drgmarti@googlemail.com</email>
    </contact>
    <contact_backup>
      <last_name>Imanol Otaegui, MD</last_name>
      <phone>+34 93 274 6155</phone>
      <email>iotaegui@vhebron.net</email>
    </contact_backup>
    <investigator>
      <last_name>David García- Dorado García, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Bassaganyas Vilarrasa, MD, PhD</last_name>
      <email>jbassaganyas.girona.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Worner Diz, MD, PhD</last_name>
      <email>fworner.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borja Ibáñez Cabeza, MD, PhD</last_name>
      <email>bibanez@cnic.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan 23</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Bardají Ruíz, MD, PhD</last_name>
      <email>abardaji.hj23.ics@gencat.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </removed_countries>
  <reference>
    <citation>Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012 Jun;33(12):1491-9. doi: 10.1093/eurheartj/ehr309. Epub 2011 Sep 14.</citation>
    <PMID>21920963</PMID>
  </reference>
  <results_reference>
    <citation>Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010 Feb 27;375(9716):727-34. doi: 10.1016/S0140-6736(09)62001-8.</citation>
    <PMID>20189026</PMID>
  </results_reference>
  <results_reference>
    <citation>White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):178-188. doi: 10.1016/j.jcin.2014.05.015. Epub 2014 Sep 17.</citation>
    <PMID>25240548</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Dorado D, García-del-Blanco B, Otaegui I, Rodríguez-Palomares J, Pineda V, Gimeno F, Ruiz-Salmerón R, Elizaga J, Evangelista A, Fernandez-Avilés F, San-Román A, Ferreira-González I. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014 Dec 20;177(3):935-41. doi: 10.1016/j.ijcard.2014.09.203. Epub 2014 Oct 7.</citation>
    <PMID>25449504</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Reperfusion Injury</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Remote Ischemic Conditioning</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Glucagon-Like Peptide-1 (GLP-1)</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Cardioprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

